An Open-Label, Single Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression

  • days left to enroll
  • participants needed
  • sponsor
    Beckley Psytech Limited
Updated on 9 April 2023


An open-label, multi-centre, Phase 2a study to evaluate the safety, tolerability and pharmacodynamics after a single intranasal dose of BPL-003 combined with psychological support, in patients with treatment resistant depression not currently taking antidepressants.


Approximately 12 eligible participants will be receive a single dose of BPL-003, given intranasally, with 12 weeks of follow-up assessments. Psychological support will be given before, during and after dosing.

Condition Treatment Resistant Depression
Treatment BPL-003
Clinical Study IdentifierNCT05660642
SponsorBeckley Psytech Limited
Last Modified on9 April 2023


Yes No Not Sure

Inclusion Criteria

Diagnosed with Major Depressive Disorder
Diagnosed with TRD defined as failure to respond to an adequate dose and duration of at least 2 pharmacological treatments
Montgomery-Asberg Depression Rating Scale score ≥24 at Screening
Clinical Global Impression - Severity ≥4 at Screening
Quick Inventory of Depressive Symptomatology - Self Rated - 16 item scale ≥13 at Screening
Willing and able to discontinue current pharmacological anti-depressant therapy

Exclusion Criteria

Current or history of schizophrenia, psychotic disorder including psychotic depression, bipolar disorder, delusional disorder, schizoaffective disorder, or any other severe psychiatric disorder
Current personality disorders
First-degree family history of schizophrenia, bipolar disorder, delusional disorder, personality disorders or schizoaffective disorder
Current alcohol or substance use disorder (other than caffeine or nicotine)
A participant who at any time, has been unresponsive to ketamine, esketamine, an adequate course of treatment with electroconvulsive therapy, or has received vagal nerve stimulation or deep brain stimulation
Suicidal ideation or behavior within the 12 months prior to the start of Screening or on Day 1 prior to dosing
Suicide attempt and/or self-injurious behavior within the last 12 months prior to Screening
Uncontrolled medical conditions e.g. hypo/hyperthyroidism, diabetes, renal failure
Seizure disorder or history of seizures (including febrile seizures)
Abnormal and clinically significant results on the physical examination, vital signs, electrocardiogram, or laboratory tests at Screening Baseline
Any nasal obstruction, blockage, or symptoms of congestion at the time of dosing, that in the Investigator's opinion may interfere with administration of the study drug
Currently receiving lithium, antipsychotics, serotonergic drugs, psychostimulants, or any other prohibited medication
Female patients who are pregnant or lactating, or of childbearing potential and not willing to use adequate forms of contraception
Male patients who are sexually active and not willing to using adequate forms of contraception
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note